THJ-2201
THJ-2201 is a synthetic cannabinoid that is the indazole analogue of AM-2201. It was first identified in illegal herbal products in Japan in 2013. It is presumed to be a potent agonist of the CB1 receptor, although it is unclear whether it is selective for this target. THJ-2201 is an Anlage II controlled substance in Germany as of May 2015. It is also banned in Sweden.
Chemistry[edit | edit source]
THJ-2201 is a synthetic cannabinoid that is the indazole analogue of AM-2201. It is structurally related to other synthetic cannabinoids including AM-2201, AM-2233, and AB-PINACA. The systematic name of THJ-2201 is naphthalen-1-yl(1-(5-fluoropentyl)-1H-indazol-3-yl)-methanone.
Pharmacology[edit | edit source]
THJ-2201 is presumed to be a potent agonist of the CB1 receptor, although it is unclear whether it is selective for this target. Synthetic cannabinoids such as THJ-2201 are often used in research to study the endocannabinoid system.
Legal status[edit | edit source]
THJ-2201 is an Anlage II controlled substance in Germany as of May 2015. It is also banned in Sweden. The legal status of THJ-2201 in other countries is unclear, but it may be controlled under analogue laws in countries such as the United States.
See also[edit | edit source]
THJ-2201 Resources | ||
---|---|---|
|
|
Translate to: East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD